A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia (DEPAKINE PASS)
Post Authorization Safety Study Assessing the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Trial Transparency email recommended (Toll free for US & Canada)
- Phone Number: option 6 800-633-1610
- Email: contact-us@sanofi.com
Study Locations
-
-
-
Chilly-Mazarin, France, 91380
- Sanofi-Aventis
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Healthcare professionals working only in Saudi Arabia AND
- Prescribers of Depakine® (sodium valiporate) at least once in the six months leading up to survey completion OR
- Obstetricians/Gynecologists who consulted at least one women of childbearing potential treated with Depakine® (sodium valproate) in the six months leading up to survey completion OR
- Pharmacists who have dispensed Depakine® (sodium valproate) in the six months leading up to survey completion
Exclusion Criteria:
- Healthcare professionals who may have conflicts of interest with the survey (i.e. employed by regulatory bodies or pharmaceutical companies)
- Healthcare professionals (or with a relative) involved in valproate-related lawsuits or associations for victims of valproate syndrome
- Healthcare professionals who are not prescribing Depakine® (sodium valproate), except for obstetricians/gynecologists (who do not prescribe Depakine® [sodium valproate])
- Healthcare professionals having started to prescribe or dispense Depakine® (sodium valproate) earlier than six months before survey completion
The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Sodium valporate
Participants are healthcare professionals completing a survey regarding women of childbearing potential using sodium valporate, prescribe or dispense the treatment
|
This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of healthcare professionals who received and read the educational materials
Time Frame: 7 months
|
7 months
|
|
|
Healthcare professionals' knowledge score
Time Frame: 7 months
|
Knowledge score is calculated as the proportion of correct responses among all questions related to knowledge
|
7 months
|
|
Healthcare professionals' behavior score
Time Frame: 7 months
|
Behavior score is calculated as the proportion of correct responses among all questions related to behavior
|
7 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Epilepsy
- Seizures
- Organic Chemicals
- Fatty Acids
- Lipids
- Acids, Acyclic
- Carboxylic Acids
- Pentanoic Acids
- Valerates
- Fatty Acids, Volatile
- Valproic Acid
Other Study ID Numbers
Other Study ID Numbers
- OBS18507
- U1111-1310-4851 (Registry Identifier: WHO ICTRP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.